0001870940-26-000028
SEC filingMixed Q1: revenue flat, operating loss widened on higher SG&A, but net loss improved and cash flow surged on working capital and cost savings.
Net loss improved to $2.4 million from $2.8 million, a 15.8% improvement. The improvement was driven by lower interest expense and the decrease in stock compensation. Diluted earnings per share improved to $(0.03) from $(0.05).
Management did not provide quantitative guidance but emphasized that selling expense investment will be calibrated to protect Adjusted EBITDA Margins. The company's ability to improve operating results depends on reversing the recent decline in cases performed. Key risks include the need to refinance its term loan and revolver by May 2027, ongoing material weaknesses in internal controls over financial reporting (related to general accounting and lease accounting), and the effectiveness of remediation efforts. The company's reliance on self-pay patients and third-party financing also exposes it to consumer discretionary spending trends.